Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.09
BEAT's Cash-to-Debt is ranked lower than
65% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. BEAT: 1.09 )
Ranked among companies with meaningful Cash-to-Debt only.
BEAT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 280.06 Max: No Debt
Current: 1.09
Equity-to-Asset 0.72
BEAT's Equity-to-Asset is ranked higher than
66% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BEAT: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
BEAT' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.16  Med: 0.77 Max: 0.92
Current: 0.72
-1.16
0.92
Debt-to-Equity 0.17
BEAT's Debt-to-Equity is ranked higher than
63% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. BEAT: 0.17 )
Ranked among companies with meaningful Debt-to-Equity only.
BEAT' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.49  Med: 0.17 Max: 0.43
Current: 0.17
-1.49
0.43
Interest Coverage 2.70
BEAT's Interest Coverage is ranked lower than
84% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. BEAT: 2.70 )
Ranked among companies with meaningful Interest Coverage only.
BEAT' s Interest Coverage Range Over the Past 10 Years
Min: 0.11  Med: 8.03 Max: No Debt
Current: 2.7
Piotroski F-Score: 4
Altman Z-Score: 11.66
Beneish M-Score: -2.30
WACC vs ROIC
9.46%
44.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 6.82
BEAT's Operating Margin % is ranked higher than
58% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. BEAT: 6.82 )
Ranked among companies with meaningful Operating Margin % only.
BEAT' s Operating Margin % Range Over the Past 10 Years
Min: -51.52  Med: -3.95 Max: 8.65
Current: 6.82
-51.52
8.65
Net Margin % 21.29
BEAT's Net Margin % is ranked higher than
96% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. BEAT: 21.29 )
Ranked among companies with meaningful Net Margin % only.
BEAT' s Net Margin % Range Over the Past 10 Years
Min: -51.61  Med: -5.77 Max: 25.65
Current: 21.29
-51.61
25.65
ROE % 38.43
BEAT's ROE % is ranked higher than
97% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. BEAT: 38.43 )
Ranked among companies with meaningful ROE % only.
BEAT' s ROE % Range Over the Past 10 Years
Min: -57.69  Med: -13.67 Max: 49.75
Current: 38.43
-57.69
49.75
ROA % 25.33
BEAT's ROA % is ranked higher than
97% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. BEAT: 25.33 )
Ranked among companies with meaningful ROA % only.
BEAT' s ROA % Range Over the Past 10 Years
Min: -48.81  Med: -8.74 Max: 33.07
Current: 25.33
-48.81
33.07
ROC (Joel Greenblatt) % 45.33
BEAT's ROC (Joel Greenblatt) % is ranked higher than
78% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. BEAT: 45.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BEAT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -195.03  Med: -24.05 Max: 56.73
Current: 45.33
-195.03
56.73
3-Year Revenue Growth Rate 10.50
BEAT's 3-Year Revenue Growth Rate is ranked higher than
65% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. BEAT: 10.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BEAT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41  Med: 0.6 Max: 52.8
Current: 10.5
-41
52.8
3-Year EBITDA Growth Rate 70.70
BEAT's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BEAT: 70.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BEAT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -27.6 Max: 70.7
Current: 70.7
0
70.7
» BEAT's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

BEAT Guru Trades in Q3 2016

Joel Greenblatt 26,153 sh (+42.37%)
Paul Tudor Jones 19,700 sh (+35.21%)
Jim Simons 1,027,200 sh (+11.21%)
Chuck Royce 476,700 sh (-11.18%)
» More
Q4 2016

BEAT Guru Trades in Q4 2016

Jim Simons 1,099,300 sh (+7.02%)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 319,409 sh (-33.00%)
» More
Q1 2017

BEAT Guru Trades in Q1 2017

Jim Simons 1,247,045 sh (+13.44%)
Chuck Royce 212,409 sh (-33.50%)
» More
Q2 2017

BEAT Guru Trades in Q2 2017

Jim Simons 1,085,600 sh (-12.95%)
Chuck Royce 177,409 sh (-16.48%)
» More
» Details

Insider Trades

Latest Guru Trades with BEAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2016-12-31 Sold Out 0.01%$15.35 - $23.35 $ 32.0064%0
Joel Greenblatt 2016-09-30 Add 42.37%$16.08 - $21.3 $ 32.0070%26,153
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8093
Compare:NAS:GHDX, NAS:ABAX, NAS:ALOG, NAS:MEDP, NAS:QDEL, NAS:VREX, NAS:NRCIB, NAS:NEO, NAS:AXDX, NAS:NTRA, NAS:FMI, NAS:HSKA, NAS:LNTH, NAS:PACB, NAS:VIVO, NAS:RDNT, NYSE:ENZ, NYSE:ARA, NYSE:NVTA, AMEX:SENS » details
Traded in other countries:C25.Germany,
Headquarter Location:USA
BioTelemetry Inc provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Its segments are healthcare, technology and research.

BioTelemetry Inc provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company operates under three segments; Healthcare, Technology and Research. These segments were previously referred to as Patient Services, Product and Research Services, respectively. The Healthcare segment, operating as CardioNet, LLC and Heartcare Corporation of America, Inc., is engaged in the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. It provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with a full spectrum of solutions, ranging from differentiated MCT services to wireless and trans telephonic event and Holter monitoring. It also provides Pacemaker and INR monitoring. It markets its services throughout the United States and receives reimbursement for the monitoring provided to patients from Medicare and other third-party commercial payors The Technology segment, operating as Braemar Manufacturing, LLC, Universal Medical, Inc. and BioTelemetry Belgium BVBA., engages in the manufacturing, engineering and development of noninvasive cardiac monitors for healthcare companies. It offers contract manufacturing services, developing and producing devices to the specific requirements set by customers. Braemar and UMI currently manufacture the cardiac monitoring devices utilized by its Healthcare segment. The Research segment, operating as Cardiocore, LLC, is engaged in central core laboratory services that provide cardiac monitoring, imaging services, scientific consulting and data management services for drug, medical treatment and device trials. The centralized services include electrocardiography (ECG), Holter monitoring, ambulatory blood pressure monitoring (ABPM), echocardiography (ECHO), multigated acquisition scan (MUGA), imaging services, protocol development, expert reporting and statistical analysis. It also provides support services that include project coordination, setup and management, equipment rental, data transfer, processing, analysis and 24/7 customer support and site training. Its data management systems enables complete customization for sponsors' preferred data specifications and its web service, CardioPortal, provides access to rich data from any web browser, without client-side plug-ins. The company markets cardiac monitoring solutions through a direct sales force to cardiologists and electrophysiologists, who are the physician specialists who most commonly diagnose and manage patients with arrhythmias. It markets research services to pharmaceutical companies, medical device companies and contract research and academic research organizations. It markets its products to physicians, hospitals and other cardiac monitoring providers. The Technology division competes directly with other original equipment manufacturers. It believes that it competes favorably based on its sui

Ratios

vs
industry
vs
history
PE Ratio 20.95
BEAT's PE Ratio is ranked higher than
76% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. BEAT: 20.95 )
Ranked among companies with meaningful PE Ratio only.
BEAT' s PE Ratio Range Over the Past 10 Years
Min: 11.28  Med: 37.24 Max: 916.88
Current: 20.95
11.28
916.88
Forward PE Ratio 22.52
BEAT's Forward PE Ratio is ranked lower than
71% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. BEAT: 22.52 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.95
BEAT's PE Ratio without NRI is ranked higher than
76% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. BEAT: 20.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
BEAT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.28  Med: 37.24 Max: 916.88
Current: 20.95
11.28
916.88
Price-to-Owner-Earnings 23.91
BEAT's Price-to-Owner-Earnings is ranked higher than
68% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. BEAT: 23.91 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BEAT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.49  Med: 28.14 Max: 115.99
Current: 23.91
12.49
115.99
PB Ratio 6.25
BEAT's PB Ratio is ranked lower than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. BEAT: 6.25 )
Ranked among companies with meaningful PB Ratio only.
BEAT' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3 Max: 7.53
Current: 6.25
0.42
7.53
PS Ratio 4.56
BEAT's PS Ratio is ranked lower than
58% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. BEAT: 4.56 )
Ranked among companies with meaningful PS Ratio only.
BEAT' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.41 Max: 5.47
Current: 4.56
0.43
5.47
Price-to-Free-Cash-Flow 48.91
BEAT's Price-to-Free-Cash-Flow is ranked lower than
69% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. BEAT: 48.91 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BEAT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.18  Med: 28.67 Max: 1795.71
Current: 48.91
5.18
1795.71
Price-to-Operating-Cash-Flow 31.42
BEAT's Price-to-Operating-Cash-Flow is ranked lower than
70% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. BEAT: 31.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BEAT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.64  Med: 20.36 Max: 1145
Current: 31.42
3.64
1145
EV-to-EBIT 68.53
BEAT's EV-to-EBIT is ranked lower than
86% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BEAT: 68.53 )
Ranked among companies with meaningful EV-to-EBIT only.
BEAT' s EV-to-EBIT Range Over the Past 10 Years
Min: -1960.8  Med: -0.7 Max: 327.4
Current: 68.53
-1960.8
327.4
EV-to-EBITDA 34.48
BEAT's EV-to-EBITDA is ranked lower than
74% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. BEAT: 34.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
BEAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -164.2  Med: 17.35 Max: 447.9
Current: 34.48
-164.2
447.9
EV-to-Revenue 4.65
BEAT's EV-to-Revenue is ranked lower than
55% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. BEAT: 4.65 )
Ranked among companies with meaningful EV-to-Revenue only.
BEAT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 1.4 Max: 9.4
Current: 4.65
0.1
9.4
Current Ratio 2.03
BEAT's Current Ratio is ranked lower than
63% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. BEAT: 2.03 )
Ranked among companies with meaningful Current Ratio only.
BEAT' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.35 Max: 7.88
Current: 2.03
0.44
7.88
Quick Ratio 1.91
BEAT's Quick Ratio is ranked lower than
59% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. BEAT: 1.91 )
Ranked among companies with meaningful Quick Ratio only.
BEAT' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.19 Max: 7.88
Current: 1.91
0.44
7.88
Days Inventory 17.69
BEAT's Days Inventory is ranked higher than
81% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. BEAT: 17.69 )
Ranked among companies with meaningful Days Inventory only.
BEAT' s Days Inventory Range Over the Past 10 Years
Min: 5.61  Med: 12.9 Max: 19.72
Current: 17.69
5.61
19.72
Days Sales Outstanding 24.89
BEAT's Days Sales Outstanding is ranked higher than
60% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. BEAT: 24.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
BEAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.89  Med: 65.49 Max: 119.19
Current: 24.89
24.89
119.19
Days Payable 38.89
BEAT's Days Payable is ranked lower than
52% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. BEAT: 38.89 )
Ranked among companies with meaningful Days Payable only.
BEAT' s Days Payable Range Over the Past 10 Years
Min: 30.45  Med: 54.23 Max: 65.87
Current: 38.89
30.45
65.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
BEAT's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. BEAT: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BEAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -102  Med: -2.9 Max: -1.6
Current: -3.1
-102
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 106.67
BEAT's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. BEAT: 106.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BEAT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.04  Med: 2.63 Max: 361.88
Current: 106.67
1.04
361.88
Price-to-Tangible-Book 12.40
BEAT's Price-to-Tangible-Book is ranked lower than
83% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. BEAT: 12.40 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BEAT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 5.2 Max: 23.97
Current: 12.4
0.76
23.97
Price-to-Intrinsic-Value-Projected-FCF 5.58
BEAT's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
86% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. BEAT: 5.58 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BEAT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.87  Med: 4.39 Max: 7.16
Current: 5.58
0.87
7.16
Price-to-Median-PS-Value 3.24
BEAT's Price-to-Median-PS-Value is ranked lower than
97% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. BEAT: 3.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BEAT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 0.96 Max: 3.65
Current: 3.24
0.33
3.65
Price-to-Graham-Number 3.39
BEAT's Price-to-Graham-Number is ranked higher than
53% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. BEAT: 3.39 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BEAT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.93  Med: 4.07 Max: 20.5
Current: 3.39
1.93
20.5
Earnings Yield (Greenblatt) % 1.45
BEAT's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. BEAT: 1.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BEAT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -585.6  Med: -3.05 Max: 9.1
Current: 1.45
-585.6
9.1

More Statistics

Revenue (TTM) (Mil) $221.02
EPS (TTM) $ 1.53
Beta1.17
Short Percentage of Float6.45%
52-Week Range $15.25 - 39.20
Shares Outstanding (Mil)32.36

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 287 387 430 476
EPS ($) 1.03 1.34 1.90 2.50
EPS without NRI ($) 1.03 1.34 1.90 2.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
28.40%
Dividends per Share ($)
» More Articles for BEAT

Headlines

Articles On GuruFocus.com
BioTelemetry, Inc. to Release Second Quarter 2017 Earnings Results on August 8, 2017 Jul 31 2017 
BioTelemetry, Inc. Completes LifeWatch AG Acquisition Jul 12 2017 
BioTelemetry, Inc. Reaches Key Milestone in Tender Offer for LifeWatch AG Jun 09 2017 
LifeWatch’s Largest Shareholders Accept BioTelemetry, Inc.’s Tender Offer for LifeWatch AG May 30 2017 
BioTelemetry, Inc. Increases Tender Offer Price and Extends Offer Period for LifeWatch AG Shares May 24 2017 
BioTelemetry, Inc. Announces Extension of the Tender Offer Period for LifeWatch AG Shares May 23 2017 
BioTelemetry, Inc. Announces the Start of the Tender Offer Period for LifeWatch AG Shares May 10 2017 
BioTelemetry, Inc. Announces Receipt of Antitrust Clearance for its Acquisition of LifeWatch AG May 08 2017 
BioTelemetry, Inc. to Release First Quarter 2017 Earnings Results on May 3, 2017 Apr 25 2017 
BioTelemetry, Inc. Issues Prospectus for Public Tender Offer to Acquire LifeWatch AG Apr 24 2017 

More From Other Websites
Zacks.com featured highlights include JA Solar Holdings, BioTelemetry, Arista Networks, Owens... Sep 22 2017
Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now Sep 21 2017
5 Momentum Stocks Powered by Driehaus Strategy Sep 21 2017
BioTelemetry, Inc. – Value Analysis (NASDAQ:BEAT) : September 19, 2017 Sep 19 2017
ETFs with exposure to BioTelemetry, Inc. : September 19, 2017 Sep 19 2017
BioTelemetry, Inc. breached its 50 day moving average in a Bearish Manner : BEAT-US : September 18,... Sep 18 2017
Does BioTelemetry Inc’s (BEAT) PE Ratio Warrant A Buy? Sep 15 2017
Can BioTelemetry (BEAT) Run Higher on Strong Earnings Estimate Revisions? Aug 30 2017
Advisory Board (ABCO) in Focus: Stock Moves 6.4% Higher Aug 30 2017
Why Biotelemetry (BEAT) Could Be an Impressive Growth Stock Aug 23 2017
The Zacks Analyst Blog Highlights: Health Insurance Innovations, BioTelemetry, Solaredge... Aug 22 2017
ETFs with exposure to BioTelemetry, Inc. : August 21, 2017 Aug 21 2017
Here's Why Investors Should Buy BioTelemetry (BEAT) Now Aug 21 2017
Trump & Terror Hint at Market Pullback: 5 Ultra-Safe Picks Aug 21 2017
Top Ranked Momentum Stocks to Buy for August 16th Aug 16 2017
BioTelemetry Hits a 52-Week High: What's Driving the Stock? Aug 16 2017
Edited Transcript of BEAT earnings conference call or presentation 8-Aug-17 9:00pm GMT Aug 11 2017
BioTelemetry, Inc. :BEAT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 Aug 10 2017
BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates Aug 09 2017
BioTelemetry posts 2Q profit Aug 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}